Allergy/Imm Medical News about Immunotherapy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu
Clinical Cancer Research, 09/15/09

Peethambaram PP et al. – Autologous active cellular immunotherapy with lapuleucel–T stimulated an immune response specific to the immunizing antigen and seemed to be well tolerated. Further clinical studies to assess the clinical benefit for patients with HER/2–neu–expressing breast, ovarian, and colorectal cancer are warranted.

<< Previous
Sleep disturbance in persistent allergic rhinitis measured using...

Next >>
Clinical stem cell therapies for severe autoimmune diseases